TScan Therapeutics, Inc. (TCRX) Reports Q3 Net Loss of $33.1M; Cash Runway Into Q4 2027
TScan reported Q3 2026 revenue of $0.6M versus $2.5M a year earlier and a net loss of $33.1M versus $35.7M. Cash and cash equivalents were $73.0M at September 30, excluding $5.0M restricted cash; the company expects funding into Q4 2027.Material DetailsContext by AI AnalystThis is an early-stage pi…